Tech entrepreneur Bryan Johnson sheds light on India's severe air pollution problem, comparing it to America's obesity issue. Despite its deadly impact, the public remains largely unaware.

Q1 2025 Management View CEO Chris Anzalone announced the closure of a significant licensing and collaboration agreement with Sarepta Therapeutics, which will provide $1.375 billion in upfront and near ...

The study states: "During a median follow-up of 11.2 years, higher tea intake was modestly associated with lower all-cause ...

While this condition can be caused by diabetes, tissue disease and neurological disorders, which damage the nerves and blood ...

The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide ...

The North Dakota legislature proposed a new bill that would require state Medicaid to fully cover obesity treatments, ...

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of diabetes and obesity, while also delivering other health benefits, such as ...

While there are no studies documenting the number of physicians taking GLP-1s, a number of physicians told the Times that they've noticed many colleagues growing thinner and sharing similar eating ...

Is obesity a risk factor or a disease? This debate shapes treatments, policies, and eating disorder care. Explore its impact ...

Gaining weight during perimenopause is common. But is it preventable? Here's what doctors say: Follow their tips to avoid ...